Table 3.

Discriminatory accuracy of PREDICT in the overall population and in subgroups.

		AUC for time-point 5 years (95% CI)
All patients	2794	73.75 (69.73–77.76)
Type of anti-HER2 therapy
Lapatinib + trastuzumab	925	72.37 (64.31–80.42)
Trastuzumab alone	936	77.67 (72.02–83.32)
Trastuzumab followed by lapatinib	933	70.64 (63.51–77.78)
Type of chemotherapy
Non-anthracycline based	322	65.18 (50.36–80.00)
Anthracycline based	2472	74.44 (70.32–78.57)
Age at randomization
≤40	495	76.09 (66.20–85.97)
41–64	1989	73.69 (68.75–78.62)
≥65	310	67.42 (56.95–77.89)
HR status
Negative	1185	71.87 (65.79–77.96)
Positive	1609	76.81 (71.58–82.04)
Number of positive lymph nodes
0	567	77.25 (65.5–89.01)
1–3	945	64.76 (54.58–74.96)
≥4	709	61.74 (55.05–68.43)
Tumor size (mm)
≤20 mm	1248	70.63 (61.83–79.44)
21–50 mm	1356	68.61 (63.27–73.94)
>50 mm	190	72.97 (63.09–82.84)

AUC area under the curve, CI confidence interval, CT chemotherapy, HR hormone receptors.